LifeStance Health Group, Inc. (LFST) Hit a 52 Week High, Can the Run Continue?

A strong stock as of late has been LifeStance Health Group (LFST). Shares have been marching higher, with the stock up 24.3% over the past month. The stock hit a new 52-week high of $13.15 in the previous session. LifeStance Health has gained 83.1% since the start of the year compared to the 5.1% gain for the Zacks Medical sector and the 23.6% return for the Zacks Medical - Outpatient and Home Healthcare industry.

What's Driving the Outperformance?

The stock has a great record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on August 6, 2026, LifeStance Health reported EPS of $0.06 versus consensus estimate of $0.03 while it beat the consensus revenue estimate by 5.08%.

For the current fiscal year, LifeStance Health is expected to post earnings of $0.16 per share on $1.7 in revenues. This represents a 700% change in EPS on a 19.68% change in revenues. For the next fiscal year, the company is expected to earn $0.23 per share on $1.94 in revenues. This represents a year-over-year change of 41.67% and 13.98%, respectively.

Valuation Metrics

LifeStance Health may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.

On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). The individual style scores for Value, Growth, Momentum and the combined VGM Score run from A through F. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.

LifeStance Health has a Value Score of D. The stock's Growth and Momentum Scores are A and C, respectively, giving the company a VGM Score of B.

In terms of its value breakdown, the stock currently trades at 80.6X current fiscal year EPS estimates, which is a premium to the peer industry average of 21.3X. On a trailing cash flow basis, the stock currently trades at 76.6X versus its peer group's average of 17X. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.

Zacks Rank

We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, LifeStance Health currently has a Zacks Rank of #2 (Buy) thanks to favorable earnings estimate revisions from covering analysts.

Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if LifeStance Health passes the test. Thus, it seems as though LifeStance Health shares could still be poised for more gains ahead.

How Does LFST Stack Up to the Competition?

Shares of LFST have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is Aveanna Healthcare Holdings Inc. (AVAH). AVAH has a Zacks Rank of #2 (Buy) and a Value Score of A, a Growth Score of A, and a Momentum Score of A.

Earnings were strong last quarter. Aveanna Healthcare Holdings Inc. beat our consensus estimate by 29.41%, and for the current fiscal year, AVAH is expected to post earnings of $0.80 per share on revenue of $2.69 billion.

Shares of Aveanna Healthcare Holdings Inc. have gained 41.5% over the past month, and currently trade at a forward P/E of 16.45X and a P/CF of 19.14X.

The Medical - Outpatient and Home Healthcare industry is in the top 21% of all the industries we have in our universe, so it looks like there are some nice tailwinds for LFST and AVAH, even beyond their own solid fundamental situation.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research